노바티스 ADR (NVS)

Jan 16, 2026

Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends - GlobeNewswire Inc.

Jan 16, 2026

Jan 12, 2026

Is Novartis AG Gaining or Losing Market Support? - Sahm

Jan 12, 2026

Jan 11, 2026

3 Dividend Stocks to Buy in 2026 and Hold Forever - Finviz

Jan 11, 2026

Jan 09, 2026

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm

Jan 09, 2026

Jan 08, 2026

New Investors: 3 Stocks to Build Your Portfolio Around in 2026 - Finviz

Jan 08, 2026

Jan 05, 2026

The Truth About Novartis AG (ADR): Is Wall Street’s Quiet Giant Your Next Power Play? - AD HOC NEWS

Jan 05, 2026

Jan 04, 2026

The Truth About Novartis AG: Is This Pharma Giant a Silent Stock Cheat Code? - AD HOC NEWS

Jan 04, 2026

Jan 04, 2026

Novartis AG (ADR): Quiet Confidence Or Complacency? A Deep Look At NVS After A Steady Climb - AD HOC NEWS

Jan 04, 2026

Dec 29, 2025

7 Newly Overvalued Stocks this Week - Morningstar

Dec 29, 2025

Dec 27, 2025

EBITDA per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets

Dec 27, 2025

Dec 26, 2025

NVS Price History for Novartis Ag ADR Stock - Barchart.com

Dec 26, 2025

Dec 22, 2025

2 Top Stocks to Buy and Hold for the Long Term - Finviz

Dec 22, 2025

Dec 19, 2025

Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts - Sahm

Dec 19, 2025

Dec 19, 2025

Pharma's $370B Bet on America: The ETF Plays for 2026 - Barchart.com

Dec 19, 2025

Dec 18, 2025

White House Readies Drug Price Deals With AbbVie, Novartis, Roche - Sahm

Dec 18, 2025

Dec 17, 2025

Novartis, Roche to reach drug pricing deal with White HouseBloomberg - Investing.com

Dec 17, 2025

Dec 15, 2025

HSBC Lifts PT on Novartis AG (NVS) to $112 From $106 - Finviz

Dec 15, 2025

Dec 14, 2025

Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.

Dec 14, 2025

Dec 12, 2025

Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Insider Monkey

Dec 12, 2025

Dec 12, 2025

Novartis (NVS) enters $1.7 billion development deal, says report - MSN

Dec 12, 2025

Dec 11, 2025

Price Over Earnings Overview: Novartis - Sahm

Dec 11, 2025

Dec 11, 2025

13 Best ADR Stocks to Invest In - Insider Monkey

Dec 11, 2025

Dec 10, 2025

Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Finviz

Dec 10, 2025

Dec 09, 2025

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Sahm

Dec 09, 2025

Dec 09, 2025

Novartis AG (NVS) Announces US FDA Approval of Itvisma - Finviz

Dec 09, 2025

Dec 09, 2025

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Sahm

Dec 09, 2025

Dec 09, 2025

Baird Financial Group Inc. Cuts Holdings in Novartis AG $NVS - Defense World

Dec 09, 2025

Dec 08, 2025

DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Dec 08, 2025

Dec 07, 2025

Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.

Dec 07, 2025

Dec 05, 2025

Free cash flow per share of Novartis AG Sponsored ADR – GETTEX:NOTA - TradingView

Dec 05, 2025

Nov 29, 2025

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz

Nov 29, 2025

Nov 26, 2025

Why Novartis Stock Topped the Market Today - sharewise.com

Nov 26, 2025

Nov 25, 2025

Novartis AG Common Stock (NYSE:NVS) Stock Quote - Markets Financial Content

Nov 25, 2025

Nov 25, 2025

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults - Sahm

Nov 25, 2025